Genetic testing during CAR-T treatment for adults
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at a patient’s genetic (molecular) information while they receive CAR-T cell therapy. The goal is to better understand how different biological factors may affect CAR-T treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must be hospitalized to receive CAR-T cell therapy as part of the hospital’s treatment program.
- Your CAR-T treatment must be through an approved (marketing-authorized) program.
- You must give written consent by signing an informed consent form.
- There are no stated exclusion conditions in the eligibility text provided.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study looks at whether it is safe and practical to collect your own stem cells and use them to support CAR T-cell therapy for certain blood cancers that have come back or did not respond. It aims to find the best way to combine these steps, which may help some people receive CAR T treatment.
This study looks at tissue samples from adults who are receiving CAR-T cell therapy for blood-related conditions. It aims to learn more about how CAR-T works and what changes happen in the body, which may help improve future care.
This trial analyzes genetic information from patients receiving a stem cell transplant or CAR-T therapy to better understand treatment outcomes. Participation may help researchers improve future therapies.
This study looks at gene patterns in people with blood cancers to better understand the disease and find possible treatments. If you are being tested for a blood cancer or have a blood cancer that came back or got worse, you may be able to join.
This study looks at immune system “fingerprints” in people who are planning to receive CAR-T cells. It may help doctors understand how the immune system responds to CAR-T and improve future care.
This study is for people with blood cancers who are treated with CAR-T cell therapy. Researchers will follow participants over time to learn more about how this therapy works in the real world.
Hear when a new Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.